Related content

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with ^99mTc

By Oliva Juan   Valdés Zodilina   Casacó Angel   Pimentel Gilmara   González Joaquín   Álvarez Irene   Osorio Martha   Velazco Milagros   Figueroa Mariela   Ortiz Rosa   Escobar Xiomara   Orozco Maiby   Cruz Julia   Franco Sonia   Díaz Mirtha   Roque Lourdes   Carr Adriana   Vázquez Ana   Mateos Cristina   Rubio María   Pérez Rolando   Fernández Luis  

Breast Cancer Research and Treatment, Vol. 96, Iss. 2, 2006-03 ,pp. : 115-121

Springer Publishing Company

Access to resources Recommend Favorite

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

By  

International Journal of Oncology, Vol. 45, Iss. 6, 2014-01 ,pp. : 2221-2231

Spandidos Publications

Access to resources Recommend Favorite

Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: Successful modification of a murine IgM to a chimeric IgG

By        

Experimental and Therapeutic Medicine, Vol. 7, Iss. 4, 2014-01 ,pp. : 849-854

Spandidos Publications

Access to resources Recommend Favorite

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma

By Choi Brian   Sondel Paul   Hank Jacquelyn   Schalch Heidi   Gan Jacek   King David   Kendra Kari   Mahvi David   Lee Li-Yin   Kim KyungMann   Albertini Mark  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 7, 2006-07 ,pp. : 761-774

Springer Publishing Company

Access to resources Recommend Favorite

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

By                            

Oncology Reports, Vol. 28, Iss. 4, 2012-01 ,pp. : 1131-1138

Spandidos Publications

Access to resources Recommend Favorite